KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Receivables (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Receivables for 17 consecutive years, with $13.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 6.03% to $13.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $13.2 billion, a 6.03% increase, with the full-year FY2025 number at $13.2 billion, up 18.89% from a year prior.
  • Receivables was $13.2 billion for Q4 2025 at Bristol Myers Squibb, roughly flat from $13.2 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $13.2 billion in Q4 2025 to a low of $8.4 billion in Q1 2023.
  • A 5-year average of $11.1 billion and a median of $11.1 billion in 2024 define the central range for Receivables.
  • Peak YoY movement for Receivables: fell 20.21% in 2022, then surged 44.1% in 2023.
  • Bristol Myers Squibb's Receivables stood at $10.8 billion in 2021, then increased by 8.01% to $11.6 billion in 2022, then increased by 11.52% to $13.0 billion in 2023, then dropped by 3.69% to $12.5 billion in 2024, then rose by 6.03% to $13.2 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Receivables are $13.2 billion (Q4 2025), $13.2 billion (Q3 2025), and $11.7 billion (Q2 2025).